Further evidence to support judicious use of antibiotics in patients with cancer

Affiliations

Editorial

J J Luke et al. Ann Oncol. 2018.

. 2018 Jun 1;29(6):1349-1351.

doi: 10.1093/annonc/mdy153.

¹ University of Chicago, Chicago, USA. Electronic address: jluke@medicine.bsd.uchicago.edu.
² City of Hope, USA.

No abstract available

Comment on

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B. Derosa L, et al. Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103. Ann Oncol. 2018. PMID: 29617710 Free PMC article.

1. Ribas A, Wolchok JD.. Cancer immunotherapy using checkpoint blockade. Science 2018; 359(6382): 1350–1355. - PMC - PubMed
1. Maier L, Pruteanu M, Kuhn M. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018; 555: 623–628. - PMC - PubMed
1. Viaud S, Saccheri F, Mignot G. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342: 971–976. - PMC - PubMed
1. Iida N, Dzutsev A, Stewart CA. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342(6161): 967–970. - PMC - PubMed
1. Sivan A, Corrales L, Hubert N. et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350: 1084–1089. - PMC - PubMed